2025
SJR Q1
JCR Q1 · 5,6
189 eşleşen makale
SCIE
Dergi ayrıntısı
International Immunopharmacology
- Yayıncı
- Elsevier B.V.
- Ülke
- Netherlands · Western Europe
- Tür
- journal
- ISSN
-
1567576918781705
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,354
- Quartile Q1
- H-Index 165
- Atıf/yayın 5,64
- Doküman (3y) 4.625
- Atıf (3y) 26.719
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 5,6
- 5Y JIF 5,7
- JCI 1,28
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Immunology Q2
- Immunology and Allergy Q1
- Pharmacology Q1
Alanlar
- Immunology and Microbiology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Immunology | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,354 | 5,6 | 5,7 | 1,28 | Q1 | 165 |
| 2024 | Q1 | Q1 | 1,239 | 4,7 | 5 | 1,24 | Q1 | 155 |
| 2023 | Q1 | Q1 | 1,167 | 4,8 | 5 | 1,24 | Q1 | 155 |
| 2022 | Q1 | Q1 | 1,1 | 5,6 | 5,6 | 1,25 | Q1 | 155 |
| 2021 | Q1 | Q1 | 1,059 | 5,7 | 5,6 | 1,21 | Q1 | 155 |
| 2020 | Q1 | Q2 | 1,152 | 4,9 | 4,6 | 1,21 | Q1 | 155 |
| 2019 | Q1 | Q1 | 0,992 | 3,9 | 3,6 | 1,15 | Q1 | 155 |
| 2018 | — | Q2 | — | 3,4 | 3,2 | 1,06 | Q1 | — |
| 2017 | Q2 | Q2 | 1,051 | 3,1 | 3,1 | 0,99 | Q1 | 155 |
| 2016 | Q2 | Q2 | 1,088 | 3 | 3,1 | — | — | 155 |
| 2015 | Q2 | Q2 | 0,966 | 2,6 | 2,8 | — | — | 155 |
| 2014 | Q1 | Q2 | 1,061 | 2,5 | 2,7 | — | — | 155 |
| 2013 | Q2 | Q2 | 0,994 | 2,7 | 2,7 | — | — | 155 |
| 2012 | Q2 | Q2 | 0,892 | 2,4 | 2,7 | — | — | 155 |
| 2011 | Q2 | Q2 | 0,828 | 2,4 | 2,6 | — | — | 155 |
| 2010 | Q2 | Q3 | 0,893 | 2,3 | 2,5 | — | — | 155 |
| 2009 | — | Q3 | — | 2,2 | 2,3 | — | — | — |
| 2008 | — | Q3 | — | 2,2 | 2,2 | — | — | — |
| 2007 | — | Q3 | — | 2,1 | 2,2 | — | — | — |
| 2006 | — | Q2 | — | 2,2 | — | — | — | — |
| 2005 | — | Q2 | — | 2 | — | — | — | — |
| 2004 | — | Q3 | — | 1,8 | — | — | — | — |
| 2003 | — | Q2 | — | 2,2 | — | — | — | — |
| 2002 | — | Q2 | — | 1,7 | — | — | — | — |
| 2001 | — | — | — | — | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | IMMUNOLOGY | SCIE | Q1 | Q1 | 42/183 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 55/356 |
| 2024 | IMMUNOLOGY | SCIE | Q2 | Q1 | 51/183 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 54/352 |
| 2023 | IMMUNOLOGY | SCIE | Q2 | Q1 | 52/181 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 50/354 |
| 2022 | IMMUNOLOGY | SCIE | Q2 | Q1 | 56/161 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 44/278 |
| 2021 | IMMUNOLOGY | SCIE | Q2 | Q1 | 59/162 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 56/279 |
| 2020 | IMMUNOLOGY | SCIE | Q2 | Q1 | 63/162 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 70/276 |
| 2019 | IMMUNOLOGY | SCIE | Q2 | Q1 | 62/159 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 63/271 |
| 2018 | IMMUNOLOGY | SCIE | Q2 | Q2 | 75/158 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 81/267 |
| 2017 | IMMUNOLOGY | SCIE | Q3 | Q2 | 80/155 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 86/261 |
| 2016 | IMMUNOLOGY | SCIE | Q3 | — | 80/151 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 91/257 |
| 2015 | IMMUNOLOGY | SCIE | Q3 | — | 87/151 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 106/255 |
| 2014 | IMMUNOLOGY | SCIE | Q3 | — | 87/148 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 118/255 |
| 2013 | IMMUNOLOGY | SCIE | Q3 | — | 74/144 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 95/256 |
| 2012 | IMMUNOLOGY | SCIE | Q3 | — | 88/137 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 113/261 |
| 2011 | IMMUNOLOGY | SCIE | Q3 | — | 92/139 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 118/261 |
| 2010 | IMMUNOLOGY | SCIE | Q3 | — | 87/134 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 128/252 |
| 2009 | IMMUNOLOGY | SCIE | Q3 | — | 86/128 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 124/237 |
| 2008 | IMMUNOLOGY | SCIE | Q3 | — | 79/121 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 120/219 |
| 2007 | IMMUNOLOGY | SCIE | Q3 | — | 78/119 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 104/205 |
| 2006 | IMMUNOLOGY | SCIE | Q3 | — | 71/117 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 94/199 |
| 2005 | IMMUNOLOGY | SCIE | Q3 | — | 73/115 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 89/193 |
| 2004 | IMMUNOLOGY | SCIE | Q3 | — | 69/111 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 94/187 |
| 2003 | IMMUNOLOGY | SCIE | Q2 | — | 52/114 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 65/185 |
| 2002 | IMMUNOLOGY | SCIE | Q3 | — | 71/119 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 86/188 |
| 2001 | IMMUNOLOGY | SCIE | — | — | — |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | — | — | — |